INHIBRX BIOSCIENCES SHARES FALL 22% AFTER CO RELEASES DATA FROM MID-STAGE STUDY OF ITS EXPERIMENTAL COMBINATION CANCER DRUG

Reuters · 1d ago

Please log in to view news